Scandion Oncology

Overcoming cancer drug resistance

Navbar
  • Research & Development
    • Pipeline
    • Clinical Development
    • Science
      • Cancer drug resistance
      • Technology Platform
      • SCO-101
  • News & Press
    • Press releases
  • Investors
    • Share information
    • Financial calendar
    • Financial Reports
      • Annual reports
      • Interim reports
    • Presentations
    • Business development
    • Analyst Coverage
    • Prospectuses
      • Subscription warrants
      • Rights Issue 2024
      • Rights Issue 2022
      • Rights Issue 2020
      • Rights Issue 2019
      • Subscription Warrant (SCOL TO 1)
      • IPO 2018
    • Corporate governance
    • General meetings
Skip to content

Press releases

  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
23 December 2019Regulatory Scandion Oncology obtains approval from the Ethics Committee on Clinical Application for SCO-101 in patients with drug-resistant metastatic colorectal cancer Download Presentation Webcast Workbook
17 December 2019 CEO Nils Brünner is interviewed by Børsen Download Presentation Webcast Workbook
16 December 2019Regulatory Anti-bacterial treatment: Novel analogues with more than tenfold higher potency identified and technical issues with the in vivo experiments Download Presentation Webcast Workbook
29 November 2019Regulatory Chairman and Vice-Chairman of the Board in Scandion Oncology A/S buy Company shares Download Presentation Webcast Workbook
29 November 2019Regulatory Scandion Oncology receives final approval from the Danish Medicines Agency for start of clinical Phase II trial in patients with drug resistant metastatic colorectal cancer Download Presentation Webcast Workbook
22 November 2019 BioStock article about Scandion Oncology Download Presentation Webcast Workbook
22 November 2019 Interview with CEO Nils Brünner in BioStock Download Presentation Webcast Workbook
21 November 2019Regulatory Scandion Oncology CEO Newsletter November 2019 Download Presentation Webcast Workbook
21 November 2019Regulatory Scandion Oncology – Interim Report Q3 2019 Download Presentation Webcast Workbook
30 October 2019 Scandion Oncology will present at Sedermeradagen on November 18, 2019, in Stockholm Download Presentation Webcast Workbook
14 October 2019Regulatory Scandion Oncology A/S receives EU-patent for SCO-101 Download Presentation Webcast Workbook
4 October 2019 Peter Høngaard – our new Chairman of the Board – is portrayed and interview by BioStock Download Presentation Webcast Workbook
  1. Frontpage

About us

Research & Development

  • Research & Development
  • Pipeline
  • Clinical Development
  • Science

News & Press

  • Press releases
  • Other news
  • Image library items
  • Video library items

Investors

  • Investors
  • Share information
  • Financial Reports
  • Presentations
  • Analyst Coverage
  • Prospectuses
  • Corporate governance
  • Events

Scandion Oncology - The Cancer Drug Resistance Company

Our vision is to overcome cancer drug resistance in order to improve lives for cancer patients and their families

© Copyright 2022 - Scandion Oncology A/S | We use cookies to improve our services | Disclaimer: Market data could be delayed. Delivered by Cision.